Sign In
Buy RGEN
$121.73
+0.600 (+0.495%)
At Close: Jun 03, 2026
7 Big Names That Could Be the Next Tesla
10:41am, Wednesday, 07'th Apr 2021
These names are major disruptors in their respective industries. Could one of them be the next Tesla?
3 Disruptive Stocks to Buy and Hold for the Next Decade
06:11am, Sunday, 28'th Mar 2021
These companies are set to keep riding upward thanks to long-term secular trends.
Why Is Repligen (RGEN) Down 12.9% Since Last Earnings Report?
12:07pm, Friday, 26'th Mar 2021
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Is Repligen (RGEN) a Great Growth Stock?
09:51am, Thursday, 25'th Mar 2021
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Repligen (RGEN).
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
07:30am, Wednesday, 17'th Mar 2021
WALTHAM, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virt
Repligen Corporation to Present at Barclays Global Healthcare Conference
07:30am, Wednesday, 03'rd Mar 2021
WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virt
Repligen (RGEN) Q4 Earnings & Sales Top, 2021 Outlook Bright
09:08am, Thursday, 25'th Feb 2021
Repligen (RGEN) reports encouraging fourth-quarter results with sales and earnings beating estimates. The company's guidance for 2021 also beats market expectations.
Repligen Corporation's (RGEN) CEO Tony Hunt on Q4 2020 Results - Earnings Call Transcript
12:39pm, Wednesday, 24'th Feb 2021
Repligen Corporation's (RGEN) CEO Tony Hunt on Q4 2020 Results - Earnings Call Transcript
Repligen's (RGEN) Q4 Earnings and Revenues Surpass Estimates
10:38am, Wednesday, 24'th Feb 2021
Repligen (RGEN) beat estimates for both earnings and revenues in the fourth quarter of 2020.
Repligen: Q4 Earnings Insights
07:47am, Wednesday, 24'th Feb 2021
Shares of Repligen (NASDAQ:RGEN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 160.00% year over year to $0.52, which beat the estimate of $
Repligen Reports Fourth Quarter and Full Year 2020 Financial Results
07:30am, Wednesday, 24'th Feb 2021
WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f
Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference
07:30am, Monday, 22'nd Feb 2021
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtu
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
01:40pm, Wednesday, 17'th Feb 2021
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen to Report Fourth Quarter and Full Year 2020 Financial Results
03:00pm, Thursday, 11'th Feb 2021
Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Compa
Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?
12:06pm, Thursday, 11'th Feb 2021
On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.
